Millions of blood pressure patients took valsartan contaminated with NDMA — a probable carcinogen — for years before massive 2018 recalls. Cancer claims continue in the ongoing personal-injury track.
Valsartan is a widely prescribed blood pressure medication. In 2018, regulators discovered that batches manufactured overseas were contaminated with NDMA and NDEA — probable human carcinogens formed during the manufacturing process — triggering one of the largest drug recalls in history.
Patients had taken contaminated pills for years before detection. Lawsuits allege they developed cancers — liver, kidney, colorectal, stomach, and others — from chronic NDMA exposure, and that manufacturers and distributors failed to control contamination or warn patients.
Federal claims are consolidated in MDL 2875 in the District of New Jersey. The economic-loss track has resolved through settlement; the personal-injury cancer track remains in active litigation.
MDL 2875's economic-loss claims resolved through settlement. The personal-injury cancer track remains in active litigation — qualifying claims continue to be evaluated and filed.
Qualification criteria change as litigation develops. The only way to know whether your experience may fit the current criteria is a review.
The Valsartan campaign is pre-selected below. Tell us what happened — a specialist will review whether your information may fit the current criteria.
You are reviewing: Valsartan Claims. Complete the form — a case specialist may follow up if your information appears to fit.
Attorney advertising. The Torts Attorney provides legal marketing and case-acquisition services and is not a law firm. Submitting this form does not create an attorney-client relationship and does not guarantee review, acceptance, or any outcome. Prior results do not guarantee similar outcomes.